Invention Grant
- Patent Title: 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
-
Application No.: US15735418Application Date: 2016-06-23
-
Publication No.: US10323027B2Publication Date: 2019-06-18
- Inventor: Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Masataka Murakami , Jinichi Yonemori , Takuto Kojima
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2015-129043 20150626; JP2015-206797 20151020
- International Application: PCT/JP2016/069189 WO 20160623
- International Announcement: WO2016/208775 WO 20161229
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D413/04 ; C07D413/06 ; C07D413/10 ; C07D417/06 ; C07D471/04 ; C07D265/22 ; C07D491/107 ; C07F7/02 ; A61P25/28 ; C07D417/10 ; C07F7/08
Abstract:
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
Public/Granted literature
- US20180162850A1 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR Public/Granted day:2018-06-14
Information query
